Atossa Therapeutics, INC. (ATOS) — 10-K Filings
All 10-K filings from Atossa Therapeutics, INC.. Browse 3 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (3)
-
Atossa's (Z)-Endoxifen Shows Promise in Breast Cancer Trials
— Mar 25, 2026 Risk: high
ATOSSA THERAPEUTICS, INC. (ATOS) is a clinical-stage biopharmaceutical company focused on oncology, particularly breast cancer, with its lead drug candidate, or -
Atossa Therapeutics Files 2024 10-K
— Mar 25, 2025 Risk: medium
Atossa Therapeutics, Inc. filed its 10-K for the fiscal year ending December 31, 2024, on March 25, 2025. The report details the company's financial performance -
Atossa Therapeutics, Inc. Files 2023 Annual Report on Form 10-K
— Apr 1, 2024 Risk: medium
ATOSSA THERAPEUTICS, INC. (ATOS) filed a Annual Report (10-K) with the SEC on April 1, 2024. Atossa Therapeutics, Inc. filed its annual report on Form 10-K for
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX